The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Independent radiologic review of GOG218, a phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian (EOC), primary peritoneal (PPC) or Fallopian tube cancer (FTC).
R. A. Burger
Consultant or Advisory Role - Genentech (U)
M. F. Brady
Research Funding - Genentech
J. Rhee
Employment or Leadership Position - Genentech
Stock Ownership - Roche
M. A. Sovak
Employment or Leadership Position - Genentech
Stock Ownership - Roche
H. Nguyen
Employment or Leadership Position - Genentech
Stock Ownership - Roche
M. A. Bookman
Employment or Leadership Position - Boehringer Ingelheim; Genentech
Consultant or Advisory Role - Genentech
Stock Ownership - Roche